hotspot -WSS

hotspot

author：fashion 2025-10-03 00:40:48 - browse：95

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Judge rejects Trump's counterclaim against E. Jean Carroll

WSS

The surgeon had a dilemma only a Nazi medical text could resolve

Medicare Advantage today, explained in one chart

Biotech venture capitalists face new demands from investors

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Elizabeth Holmes banned from government health programs

How digital therapeutics firms are pivoting after Pear's bankruptcy

Wikipedia

hotspot

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

How digital therapeutics firms are pivoting after Pear's bankruptcy

Alkermes shareholders re

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Humana cuts profit projections as Medicare Advantage costs soar

Medicare proposal to cover medical devices draws a mixed reaction

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

23andMe had bad news about my health. I wish a person had delivered it

Germany receives 178 compensation applications from gay servicepeople over discrimination

explore

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Dewpoint Therapeutics lays off staff after losing partnerships

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Test for long Covid? Researchers find new clue in blood samples

Judge rejects Trump's counterclaim against E. Jean Carroll

entertainment

leisure time

leisure time

hotspot